Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C28H33ClN2 |
| Molecular Weight | 433.028 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1
InChI
InChIKey=MOYGZHXDRJNJEP-UHFFFAOYSA-N
InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3
DescriptionCurator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html
Buclizine, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. The following side/adverse effects have been selected on the basis of their potential clinical significance: drowsiness; Incidence less frequent; blurred vision; dryness of mouth, nose, and throat; headache; nervousness, restlessness, or trouble in sleeping; upset stomach. The following drug interactions have been selected on the basis of their potential clinical significance: alcohol; anticholinergics or other medications with anticholinergic activity; apomorphine.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Preventing | BUCLADIN-S Approved UseFor prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems). |
|||
| Preventing | BUCLADIN-S Approved UseFor prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems). |
|||
| Palliative | Migraleve pink Approved UseTreating nausea and headache associated with migraine attacks that are not relieved by paracetamol, ibuprofen or aspirin alone. Launch Date2015 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.45 μg/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.22 μg × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.3 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
BUCLIZINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Quantitation of buclizine hydrochloride in pharmaceutical formulations and human serum by RP-HPLC. | 2006 Oct |
|
| Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method. | 2010 Dec |
|
| Simultaneous determination of gliquidone, fexofenadine, buclizine, and levocetirizine in dosage formulation and human serum by RP-HPLC. | 2010 May-Jun |
Patents
Sample Use Guides
50 mg thirty minutes before travel. Dose may be repeated every four to six hours as needed. Usual adult prescribing limits - up to 150 mg daily.
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1178B2VD9B
Created by
admin on Sat Dec 16 01:28:51 GMT 2023 , Edited by admin on Sat Dec 16 01:28:51 GMT 2023
|
PRIMARY | |||
|
163837-51-2
Created by
admin on Sat Dec 16 01:28:51 GMT 2023 , Edited by admin on Sat Dec 16 01:28:51 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
